MIRAMAR, FL, May 18, 2022 (GLOBE NEWSWIRE) — Stemtech Corporation (“Stemtech”) (OTCQB: STEK), an innovative nutraceutical company pioneering stem cell nutrition, today announced that the company had been approved for listing on the OTCQB® Venture Market (the OTCQB®), which is operated by OTC Markets Group, Inc.
“This is a significant milestone in our company’s history,” said Charles S. Arnold, Stemtech’s president and CEO. “We are delighted that OTC Markets has approved our move to OTCQB®, which we believe will significantly improve our exposure to high quality investors. Our upgrade demonstrates that we are committed to meeting the disclosure requirements imposed by OTC Markets for this level, including financial reporting, annual audit and management certification of information relevant to existing and potential shareholders. Additionally, we will participate in the OTC Markets Virtual Investor Conferences.
“Our going public is a positive first step towards raising our profile in the investment community and in our industry,” Mr. Arnold continued. “Recently, we were honored to receive recognition for the momentum we are getting in the direct selling industry.” As of April 28, 2022, Stemtech has been recognized as a business in motion on the Business For Home Momentum Rank list. The Momentum Rank List measures a variety of factors from leading companies in the direct selling industry to determine which companies in the industry are showing positive momentum. Factors include, but are not limited to, activity rate, online visibility, growth, and business relevance. Stemtech moved up 108 places in the rankings from a year earlier, to a ranking of 159 out of a total of 722 top companies in the industry.
Over the past few weeks, as of May 17, 2022, Stemtech has moved up an additional 61 spots in the Momentum Rankings list to reach a ranking of 98 out of 722 top companies in the industry. The results can be viewed on the company’s website at https://www.businessforhome.org. Business For Home is a leading publisher and authority in the direct selling industry, publishing facts, figures and news related to the network marketing industry. According to Business For Home, their website receives approximately 10 million international visitors, the majority of which are network marketing professionals.
About Stemtech Corporation
Stemtech Corporation, a leading nutraceutical company with a direct sales distribution model, was founded on April 18, 2018, after acquiring the operations of its predecessor Stemtech International, Inc. which was founded in 2005. From 2010 to 2015 , Stemtech International, Inc. , has been recognized four times on the Inc. 5000 fastest growing companies listing. In 2018, the Company underwent an extensive management reorganization and continued operations under new management. Stemtech specializes in creating products and formulas protected by patents in the United States and certain international markets. The company’s patented formulas promote the release, circulation and migration of the body’s adult stem cells from its bone marrow. The Company markets its products under the following brands: RCM System, stemrelease3™, Stemflo® MigraStem®, OraStem® (Oral Health Care) and D-Fuze™ (EMF Blocker). Its products are all-natural and herbal and manufactured under cGMP (Current Good Manufacturing Practices) under the auspices of the Dietary Supplement Health and Education Act (DSHEA). For more information, please visit www.stemtech.com.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements identified by words such as “believes ‘, ‘expects’, ‘plans’, ‘estimates’, ‘intends’, ‘plans’, ‘target’, ‘projects’ and similar expressions. The statements in this release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those set forth in forward-looking statements. Many factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, challenges inherent in new product development initiatives, the effect any competing products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is needed to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any government review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our last 10-K filed April 1, 2022. We undertake no obligation to update any forward-looking statement or information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Stemtech Corporation that are tolerated by the Company must come from the Company itself and bear our name as the source.
For more information, contact:
Investors: Frank J. Pena, 908-675-0581, [email protected]